Market revenue in 2023 | USD 160.5 million |
Market revenue in 2030 | USD 194.4 million |
Growth rate | 2.8% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.52% in 2023. Horizon Databook has segmented the Middle East & Africa point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of chronic conditions, such as cancer, cardiovascular diseases, and other diseases is expected to accelerate the market growth. According to WHO estimates in 2020, cancer incidence in the Middle East are expected to double by 2030. Around 9 out of 22 countries in MEA did not have optimal operational facilities to deal with cancer.
Economic development and the presence of high unmet healthcare needs—witnessed in emerging markets such as South Africa—are primary factors driving the market growth. Hence, the presence of major untapped opportunities and high need for early diagnosis of diseases are the factors anticipated to boost the market. There is a high prevalence of communicable & infectious diseases in this region. However, ethical reasons, poor infrastructure, and affordability might hamper market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa point-of-care molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account